Название продукции:2-(2,6-Dichlorophenyl)acetonitrile

IUPAC Name:2-(2,6-dichlorophenyl)acetonitrile

CAS:3215-64-3
Молекулярная формула:C8H5Cl2N
Чистота:95+%
Номер в каталоге:CM252193
Молекулярная масса:186.04

Упаковочная единица Доступно для заказа Цена ($) Количество
CM252193-100g in stock Ʌȁ

Только для использования в НИОКР..

Форма запроса

   refresh    

Информация о продукции

Номер CAS:3215-64-3
Молекулярная формула:C8H5Cl2N
Точка плавления:-
Smiles-код:C1=CC=C(C(=C1Cl)CC#N)Cl
Плотность:
Номер в каталоге:CM252193
Молекулярная масса:186.04
Точка кипения:286.9°C at 760 mmHg
Номер Mdl:MFCD00001901
Хранение:Store at room temperature.

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Neflamapimod
Dementia with Lewy Bodies (DLB) is a rapidly progressive neurodegenerative disorder with a significant aging population and unmet health need. Alterations in p38 mitogen-activated protein kinases (MAPKs) are found to contribute to the neurodegenerative process in Alzheimer's disease (AD) and related dementias.
CervoMed’s Neflamapimod (VX-745) is an oral, brain penetrant, small molecule inhibitor of the protein kinase p38α. It is designed to specifically target the mechanisms that cause dysfunction and degeneration of neurons in the basal forebrain cholinergic system. Neflamapimod has the potential of reversing synaptic dysfunction in the basal forebrain. The positive phase 2a data was published in Nature Communications, Neurology, and JPAD. Neflamapimod was granted Fast Track Designation by the FDA for DLB, and phase 2b enrollment was completed in June, 2024.